APA

Adams S., Loi S., Toppmeyer D., Cescon D. W., De Laurentiis M., Nanda R., Winer E. P., Mukai H., Tamura K., Armstrong A., Liu M. C., Iwata H., Ryvo L., Wimberger P., Rugo H. S., Tan A. R., Jia L., Ding Y., Karantza V. & Schmid P. (20200324). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Adams S, Loi S, Toppmeyer D, Cescon D W, De Laurentiis M, Nanda R, Winer E P, Mukai H, Tamura K, Armstrong A, Liu M C, Iwata H, Ryvo L, Wimberger P, Rugo H S, Tan A R, Jia L, Ding Y, Karantza V and Schmid P. 20200324. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Adams S., Loi S., Toppmeyer D., Cescon D. W., De Laurentiis M., Nanda R., Winer E. P., Mukai H., Tamura K., Armstrong A., Liu M. C., Iwata H., Ryvo L., Wimberger P., Rugo H. S., Tan A. R., Jia L., Ding Y., Karantza V. and Schmid P. (20200324). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Adams S, Loi S, Toppmeyer D, Cescon D W, De Laurentiis M, Nanda R, Winer E P, Mukai H, Tamura K, Armstrong A, Liu M C, Iwata H, Ryvo L, Wimberger P, Rugo H S, Tan A R, Jia L, Ding Y, Karantza V and Schmid P. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. : Annals of oncology : official journal of the European Society for Medical Oncology. 20200324.